A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa

NCT01154166 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

347

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: ReQuip PR
DRUG: Placebo

Sponsor

GlaxoSmithKline